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Abstract  13
Lupine protein hydrolysates (LPHs) were obtained from a lupine protein isolate (LPI) 14
by enzymatic hydrolysis using two proteases, Izyme AL and Alcalase 2.4 L, and their 15
potential anti-inflammatory capacities were studied by determining their in vitro 16
inhibition of the following enzymes that are involved in the inflammatory process: 17
phospholipase A2 (PLA2), cyclooxygenase 2 (COX-2), thrombin, and transglutaminase 18
(TG). The strongest inhibitory activities toward PLA2 and TG were found in the 19
hydrolysates obtained by hydrolysis with Izyme and subsequently with Alcalase, with 20
more than 70% inhibition obtained in some cases. All of the hydrolysates tested 21
inhibited more than 60% of the COX-2 activity. In no case did the percentage of 22
thrombin activity inhibition exceed 40%. The best inhibitory activities were found in the 23
LPH obtained after 15 min of hydrolysis with Alcalase and in the LPH obtained after 60 24
min of hydrolysis with Izyme followed by 15 min of hydrolysis with Alcalase. Enzyme 25
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kinetic analyses were conducted to determine the Km and Vmax parameters of these two 26
hydrolysates using the Lineweaver-Burk equation. Both hydrolysates competitively 27
inhibited the thrombin and PLA2 activities. In the case of COX-2 and TG, the inhibition 28
appeared to be the mixed type. 29
Keywords: lupine protein hydrolysates; anti-inflammatory activity; bioactive peptides. 30
31
1. Introduction 32
Chronic inflammation is involved in the onset and development of numerous chronic 33
diseases, such as cardiovascular diseases, cancer, diabetes, obesity, arthritis, 34
neurological diseases, pulmonary diseases, psychological diseases, and autoimmune 35
diseases (Sung, Prasad, Gupta, Patchva, & Aggarwal, 2012). Inflammation is one of the 36
complex biological responses of the immune system of an organism. In the initial steps, 37
the inflammatory response is mediated by phospholipase A2 (PLA2), which is elevated 38
in many inflammatory disorders. PLA2 hydrolyses the sn-2 ester bond of 39
glycerophospholipids to produce free fatty acids, particularly arachidonic acid (AA), 40
and lysophospholipids (Yedgar, Cohen, & Shoseyov, 2006). AA is metabolised mainly 41
via the cyclo-oxygenase (COX) and lipo-oxygenase enzymatic pathways to produce 42
diverse families of eicosanoids, including prostaglandins (PGs), thromboxanes, and 43
leukotrienes. These eicosanoids are involved in the development of many pathological 44
conditions, particularly inflammation-related processes (Yedgar et al., 2006). 45
There is a close relationship between inflammation and coagulation. Inflammation-46
induced coagulation is due to tissue factor, which produces thrombin generation (Levi 47
& van der Poll, 2005). Thrombin is a trypsin-like serine protease that has a central role 48
in haemostasis and thrombosis. Once formed, thrombin cleaves fibrinogen to produce 49
the fibrin mesh of the blood clot (Cirino, Cicala, Bucci, Sorrentino, Maraganore, & 50
Stone, 1996). Thrombin also activates transglutaminase or factor XIII, which cross-links 51
fibrin molecules via the formation of interchain - (-glutamyl)-lysine isopeptide bonds 52
and stabilises the clot by preventing its hydrolysis by proteases (Moreno, 2006).  53
Diet is thought to be one of the major risk factors for the development of chronic 54
diseases. Thus, modifying the diet could prevent or delay these diseases (Prasad, Sung, 55
& Aggarwal, 2012). Some dietary agents have shown the potential to inactivate 56
inflammatory molecules by direct binding. Recent studies have provided evidence that 57
peptides can modify crucial regulatory functions of inflammatory processes (Fernandes, 58
Schmidhuber, & Brain, 2009). There are many reports about synthetically derived anti-59
inflammatory peptides (Rita, Anna, & Susanna, 2013). However, few studies have 60
examined the effect of plant protein hydrolysates on inflammatory markers. It has been 61
reported that soybean protein hydrolysates reduce the level of some of these markers 62
(Vernaza, Dia, Gonzalez de Mejia, & Chang, 2012). 63
Lupine (Lupinus angustifolius L.) is an herbaceous plant typical of the Mediterranean 64
region. Lupine seeds can be incorporated as a protein source in both animal feed and in 65
a variety of human foods. Lupine flour is rich in protein (20-40%), and this content can 66
be increased to more than 90% in protein isolates (Lqari, Vioque, Pedroche, & Millán, 67
2002). Lupine protein hydrolysates (LPHs) have shown bile-acid binding activity so 68
may have potential applications for reducing cholesterol in hypercholesterolemic 69
patients (Yoshie-Stark & Wäsche, 2004). More recently, lupine proteins have been 70
shown to exert hypotensive and hypotriglyceridemic effects in vivo (Cam & Gonzalez 71
de Mejia, 2012), but there are no reports of their anti-inflammatory activity. 72
The objective of this work was to determine the effect of LPHs on the activity of four 73
enzymes implicated in the inflammatory process: PLA2, COX-2, thrombin, and TG. 74
LPHs were obtained by hydrolysis of lupine protein isolate (LPI) with Izyme and 75
Alcalase, two food-grade proteases produced by Novozymes. Izyme has trypsin-like 76
activity whereas Alcalase is a non-specific endoprotease. Both trypsin and Alcalase have 77
been previously used for the generation of bioactive peptides (Korhonen & Pihlanto, 78
2006). Samples were collected after different periods of incubation, and the activity of 79
the above mentioned enzymes was tested in presence of LPHs with different degrees of 80
hydrolysis. The LPHs that exhibited more inhibitory activity were selected, and their 81
enzyme kinetic parameters (Km, Vmax) were determined.  82
83
2. Materials and methods 84
2.1. Materials 85
The L. angustifolius seeds were provided by Koipesol Semillas, S.A. (Seville, Spain). 86
Izyme AL (564 EU/mL) and Alcalase 2.4 L (2.4 AU/g) were provided by Novozymes 87
(Bagsvaerd, Denmark). PLA2 from bovine pancreas, albumin (human, essentially fatty 88
acid-free), thrombin from bovine plasma, antithrombin III (AT III), tosyl-gly-pro-arg-p-89
nitroanilide acetate salt (Chromozym), heparin sodium salt, protamine sulfate salt from 90
salmon, TG from guinea pig liver, monodansylcadaverine (dansyl-CAD), dextran-91
coated charcoal, DL-dithiothreitol (DTT), 2-mercaptoethanol, cystamine 92
dihydrochloride, COX-2 human, AA from porcine liver, N, N, N ', N'-tetramethyl p-93
phenylenediamine (TMPD), flunixin meglumine, and hematin (porcine) were purchased 94
from Sigma Chemical Co. (St. Louis, MO, USA). 1-palmitoyl-2-pyrenedecanoyl 95
phosphatidylcholine (10-pyrene-PC) was purchased from Cayman Chemical (Ann 96
Arbor, MI, USA). Bovine milk casein was obtained from Calbiochem (Merck Group, 97
Darmstadt, Germany). Iodoacetamide was purchased from Merck (Darmstadt, 98
Germany).  99
2.2. Methods  100
2.2.1. Obtaining the lupine protein isolate 101
The LPI was obtained using the method of Lqari et al. (2002). Briefly, defatted lupine 102
flour was extracted with 0.25% Na2S03 (w/v) at pH 10.5 for 1 h. After centrifuging the 103
extract at 7500 rpm for 15 min, the supernatant was recovered, and the pellet was 104
extracted again. Both of the supernatants were adjusted to the isoelectric point of lupine 105
proteins (pH 4.3). The resulting precipitate was washed with distilled water adjusted to 106
pH 4.3 and centrifuged to remove residual salts and other non-protein compounds. 107
Finally, the precipitated proteins were lyophilised and stored at room temperature. 108
2.2.2. Hydrolysis of the lupine protein isolate 109
Hydrolysis was conducted in a bioreactor under stirring at a controlled pH and 110
temperature. The LPI was suspended in distilled water (10% w/v), and two types of 111
hydrolysis were performed: one with Izyme followed by Alcalase and one using only 112
Alcalase. The following conditions were used. 113
Hydrolysis with Izyme and Alcalase: First, the LPI was hydrolysed with Izyme for 1 h 114
at pH 10, 50 ºC, and E/S = 100 EU/g protein. Then, a second hydrolysis with Alcalase 115
at pH 8, 50º C, and E/S = 0.3 AU/g protein was conducted for 1 h.  116
Hydrolysis with Alcalase: The LPI was hydrolysed with Alcalase for 1 h at pH 8, 50 ºC, 117
and E/S = 0.3 AU/g protein. 118
Samples were taken at different times, and enzymes were inactivated by heating at 85ºC 119
for 15 min. The supernatants obtained from centrifugation at 8000 rpm for 15 min 120
constituted the LPHs. The LPHs obtained using Izyme followed by Alcalase were 121
designated 0I, 15I, 30I, 60I, 60I+15A, 60I+30A, and 60I+60A. The LPHs obtained 122
using Alcalase were designated 0A, 5A, 10A, 15A, 20A, 25A, 30A, and 60A. The 123
number indicates the time of hydrolysis in minutes. 124
2.2.3. Determination of the degree of hydrolysis (DH) 125
The DH, defined as the percentage of peptide bonds cleaved, was determined by the 126
TNBS method according to Adler-Nissen (1979). The total number of amino groups 127
was determined in a sample that had been 100% hydrolysed at 110° C for 24 h in 6 N 128
HCl. 129
2.2.4. Determination of protein and peptide content  130
The protein concentrations were determined by elemental microanalysis as % nitrogen 131
content × 6.25 using a Leco CHNS-932 analyser (St. Joseph, MI, USA). 132
2.2.5. PLA2 activity assay  133
The PLA2 activity was evaluated in vitro by measuring the fluorescence produced by its 134
hydrolysis of the 10-pyrene-PC substrate (Cunningham, Maciejewski, & Yao, 2006). 135
PLA2 was dissolved in a solution of 50 mM Tris, 0.1 M NaCl, and 2 mM CaCl2 with 136
0.25% fatty acid-free albumin (pH 7.4) added to a final concentration of 0.5 mg/mL. 137
The substrate (supplied in chloroform) was dried under a nitrogen stream, dissolved in 138
absolute ethanol, and stored at -20° C prior to use. A 5 µM solution of substrate was 139
prepared in the same buffer used for the enzyme but without albumin. The fluorescence 140
at 355 nm excitation/420 nM emission was measured using a fluorescence microplate 141
reader (Fluoroskan Ascent FL, Thermo Fisher Scientific Inc., Waltham, MA, USA). 142
The reactions were evaluated for 60 min at 25° C. The concentration of the LPHs was 143
0.6 mg/mL. A negative control without LPHs and a positive control (0.6 mg/mL 144
flunixin meglumine in the well) were used. 145
2.2.6. COX 2 activity assay 146
The COX-2 activity was determined according to the method described by Somvanshi 147
et al. (2007) with some modifications. An aliquot of 0.35 µL of commercial COX-2 was 148
incubated with 5 µL of LPHs (at 70 µg protein/µL), and 95 µL of 100 mM Tris, 1 mM 149
EDTA, and 2 µM hematin pH 8.3 for 1 h at room temperature. The reaction was 150
initiated by adding 50 µL of 1.6 mM arachidonic acid and 50 µL of 0.8 mM TMPD 151
dissolved in the same buffer but without hematin and preincubated for 30 min at room 152
temperature. A control without LPHs and a positive control (1.24 mg/mL flunixin 153
meglumine in the well) were used. TMPD oxidation was determined 154
spectrophotometrically by the absorbance at 610 nm using a Multiskan Spectrum 155
microplate reader (Thermo Labsystem). The initial rate of the reaction was measured 156
during the first 21 s, and the percentage inhibition was calculated. 157
2.2.7. Thrombin activity assay158
The thrombin activity was determined by following the increase in the absorbance at 159
405 nm that accompanies hydrolysis of the chromogenic substrate Chromozym (Ialenti 160
et al., 2001). Fifty microlitres of LPH (at 70 µg protein/µL) was preincubated for 1 h 161
with 5 µL of enzyme (0.136 µg/mL) at room temperature. Then, the mixture was 162
resuspended in 1.45 mL of 50 mM Tris and 150 mM NaCl pH 8.3. The reaction was 163
initiated by adding 0.5 mL of 0.3 mM substrate. The absorbance at 405 nm was 164
measured for 5 min in a Du 640 spectrophotometer (Beckman Coulter). Heparin and AT 165
III were used as the positive control. AT III is a glycoprotein that inactivates several 166
enzymes involved in clotting. The affinity of AT III for thrombin is enhanced by the 167
action of heparin. For this reason, 30 µL of AT III (4.04 µg/mL) and 15 µL of heparin 168
(3.74 g/mL) were incubated for 1 h at room temperature. This mixture was suspended in 169
1.455 mL of assay buffer and preincubated for 1 h with 5 µL of enzyme (0.136 µg/mL) 170
at room temperature. Afterwards, 0.5 mL of 0.3 mM substrate was added, and the 171
absorbance was measured. A negative control lacking LPHs was used.  172
2.2.8. Transglutaminase activity assay 173
The method described by Wu & Tsai (2006) was used with some modifications. This 174
method is based on the TG-catalysed incorporation of the fluorescent substrate dansyl-175
CAD into casein and the subsequent separation of the unreacted fluorescent molecules. 176
The lyophilised enzyme (4.1 U/mg protein) was dissolved in water to a final 177
concentration of 1 mg/mL, and 100 µL aliquots were stored in vials at -80° C until use. 178
Three microliters of enzyme was added to 3 µL of each LPH sample (70 µg protein/µL) 179
and 24 µL of 10 mM Tris buffer pH 7.5, 1 mM EDTA, and 0.025% (v/v) 2-180
mercaptoethanol in the wells of a fluorescence microplate that was incubated at room 181
temperature for 60 min. Then, 30 µL of 100 mM Tris pH 9, 10 mM DTT, 20 mM CaCl2,182
5 mg/mL casein and 100 µM dansyl-CAD was added and incubated at 37° C for 30 183
min. The reaction was stopped by adding 60 µL of 2 mM iodoacetamide (prepared 184
fresh) for a 2 min incubation on ice. Then, 150 µL of dextran-coated charcoal at 10 185
mg/mL was added. The microplate was centrifuged in an Allegra X-22 R centrifuge 186
model (Beckman Coulter) at 1000 rpm for 15 min to pellet the unreacted dansyl-CAD. 187
The supernatants (100 µL) were carefully withdrawn, and the fluorescence intensity was 188
measured in a microplate reader at excitation and emission wavelengths of 340 and 535 189
nm, respectively. The enzyme activity was expressed as the net fluorescence per well, 190
which reflects the amount of product formed in the reaction. A control without an 191
inhibitor and a positive control with 0.54 mg/mL cystamine dihydrochloride were used. 192
2.2.9. Determination of the kinetic constants 193
The Michaelis constants (Km and Vmax) in the presence of the most effective LPHs were 194
calculated for each enzyme by performing activity assays with different substrate 195
concentrations and using Lineweaver-Burk equations.  196
2.2.10. Statistical analysis 197
The data are expressed as the mean ± standard deviation of three independent 198
determinations. The statistical analysis was performed with OriginPro 8 SR0 199
(OriginLab Corporation (Northampton, MA, USA)). The data were analysed using a 200
one-way ANOVA, followed by Holm-Bonferroni tests for multiple comparisons. 201
Differences were considered to be significant at P<0.05. 202
3. Results and discussion203
3.1. Study of the degree of hydrolysis 204
LPI was hydrolysed using two food-grade commercial enzymes, Izyme and Alcalase. 205
Hydrolysis with Izyme resulted in a DH of approximately 9% (Figure 1A); the DH was 206
not increased by increasing the time of hydrolysis or the enzyme/substrate ratio, which 207
may be due, partially, to the lysine-plus-argentine content of the LPI (15%, data not 208
shown). In analysing the results, it was found that Izyme performance was 209
approximately 60%. Because most bioactive peptides known at present contain 2 to 20 210
amino acids and have molecular masses of less than 6000 Da (Sarmadi & Ismail, 2010), 211
a second hydrolysis using Alcalase was performed after hydrolysis with Izyme. In this 212
way, the DH was rapidly increased up to 30%. 213
The rate of hydrolysis of the LPI using only Alcalase was rapid during the first 10 min 214
and then remained almost stable for the following 50 min, reaching a maximum DH of 215
26% (Figure 1B). A high reaction rate has also been observed for the hydrolysis of other 216
plant proteins using Alcalase (Yust, Millán-Linares, Alcaide-Hidalgo, Millán, & 217
Pedroche, 2012). 218
3.2. Inhibition of enzymes involved in the inflammatory pathway  219
3.2.1. Inhibition of PLA2 activity 220
PLA2 enzymes are low molecular weight proteins that catalyse hydrolysis at the sn-2 221
position of membrane phospholipids, releasing unsaturated fatty acids and liberating 222
AA, a precursor of eicosanoids, including prostaglandins and leukotrienes. These 223
enzymes have been implicated in diverse physiological processes, including asthma, 224
inflammation, carcinogenesis, haemostasis, parturition, maintenance of renal function, 225
pain and fever; indeed, these enzymes are detected in the serum and biological fluids of 226
patients with various inflammatory, autoimmune and allergic disorders (Triggiani, 227
Granata, Frattini, & Marone, 2006). In recent investigations, plant proteins have been 228
shown to act as antioxidants, inhibiting lipid peroxidation, and as anti-inflammatory 229
agents due to their ability to inhibit PLA2. One example is turmerin, a protein from 230
Curcuma longa L. (Chethankumar, 2010).  231
Hydrolysis of LPI with Izyme for 60 min increased inhibition of PLA2 activity up to 232
68% (Figure 2.A). This value is similar to that showed by the positive control, flunixin. 233
A second step of hydrolysis with Alcalase did not increase or decrease inhibition of 234
PLA2, which may be attributed to the destruction of inhibitory peptides and the 235
generation of new ones throughout the hydrolytic process. Likewise, the hydrolysis with 236
Alcalase produces smaller peptides which may be more easily absorbed from the 237
gastrointestinal tract. Regarding LPHs obtained using Alcalase, only LPH 60A showed 238
higher PLA2 inhibition than 0A (Figure 2.B). However, the achieved inhibition was 239
lower than the obtained when LPI was hydrolysed with Izyme and Alcalase. 240
3.2.2. Inhibition of COX-2 activity 241
COX catalyses the addition of two moles of molecular oxygen to arachidonic acid, 242
forming prostaglandin G2 and converting G2 to PGH2. Hence, COX performs the critical 243
initial reaction that leads to the formation of pro-inflammatory prostaglandins, 244
thromboxanes and prostacyclins. COX exists in two isoforms, COX-1 and COX-2. 245
COX-1 is considered a constitutive enzyme, whereas COX-2 is an inducible enzyme 246
whose expression occurs in inflammatory cell types and tissues (Gierse, Koboldt, 247
Walker, Seibert, & Isakson, 1999). COX-2 mediates prostaglandin synthesis (PGE2), 248
which in turn promotes cell proliferation and cytokine secretion and suppresses immune 249
surveillance by mechanisms such as the inhibition of Th1 activation and IL-2 secretion 250
and the suppression of dendritic cells via IL-10. The COX-2 pathway was shown to 251
participate in cases of inflammatory diseases, such as Crohn’s disease, and in colon 252
carcinoma (Kanterman, Sade-Feldman, & Baniyash, 2012). 253
It should be noted that untreated lupine proteins highly inhibited COX-2 activity (Figure 254
3). The differences between the inhibitory activities of 0I and 0A may be due to the 255
effect of the different pH (10 and 8 respectively), which may alter the structure of the 256
proteins. Hydrolysis of the LPI with Izyme followed by Alcalase did not improve its 257
ability to inhibit COX-2, showing all LPHs tested more than 70% of COX-2 inhibition 258
(Figure 3.A). When the LPI was hydrolysed using only Alcalase, the highest inhibitory 259
activity was observed in the hydrolysate obtained after 15 min of treatment (90%) 260
(Figure 3.B). The inhibition values are remarkable when compared with that of the 261
reference inhibitor, flunixin, which inhibited 98% of COX-2 activity at a concentration 262
slightly less than that of the LPHs (1.24 mg/mL versus 1.75 mg/mL). Moreover, the 263
LPHs are peptide mixtures and only some of the peptides may inhibit COX-2; therefore, 264
purification may result in substances with higher inhibitory activities (Li, Zhou, Huang, 265
Sun, & Zeng, 2012).  266
3.2.3. Inhibition of thrombin activity 267
Thrombin acts in the coagulation cascade by catalysing the conversion of fibrinogen 268
into fibrin and, consequently, achieving the formation of a blood clot. Furthermore, 269
thrombin has been found to exert a number of pro-inflammatory and mitogenic effects 270
and has been linked to the development of vascular disease (Morris, Winyard, Blake, & 271
Morris, 1994). Specifically, thrombin stimulates the production of proinflammatory 272
cytokines and interleukins, such as TNF-α, IL-1 and IL-6, and the production of 273
monocyte chemotactic protein (MCP-1) by vascular endothelial cells (Strande & 274
Phillips, 2009). Hydrolysing the lupine proteins with Izyme for 30 min increased their 275
thrombin inhibition by up to 36% (Figure 4.A). When the time of hydrolysis, and 276
therefore the DH, was increased, the thrombin inhibitory activity was reduced to the 277
initial values. When the LPI was hydrolysed only with Alcalase, the highest inhibitory 278
activity was observed after 15 min of treatment. As in the hydrolytic process with Izyme 279
plus Alcalase, there was not a direct correlation between the increase of the DH and the 280
inhibition of thrombin activity (Figure 4.B). Those results may be due to the destruction 281
of the potentially anti-inflammatory peptides generated initially and the production of 282
new ones in such a way that the thrombin inhibition by LPHs did not depend on the DH 283
but on the generation of specific peptides. These results are similar to those regarding 284
the hypocholesterolaemic and antioxidant effects reported by Yust et al. (2012). 285
3.2.4. Inhibition of TG activity 286
TG is a calcium-dependent enzyme that catalyses the covalent crosslinking of the γ-287
carboxamide groups of peptides bound to glutamine residues with the ε-amino groups of 288
peptides bound to lysine residues. In addition, the involvement of TG-2 in the 289
pathogenesis of chronic inflammatory diseases, such as liver cirrhosis, lung fibrosis, and 290
rheumatoid arthritis, has been suggested (Kumar & Metha, 2013). Moreno (2006) 291
reported that short peptides termed antiflammins have anti-inflammatory effects due, at 292
least in part, to their ability to inhibit TG-2.  293
The rates of TG inhibition by the LPHs obtained with Izyme and Alcalase and with 294
Alcalase are shown in Figures 5.A and 5.B, respectively. The LPHs prepared using 295
Izyme had little effect on the activity of TG, but the addition of a second round of 296
hydrolysis using Alcalase led to 70% inhibition of TG. This result was similar to that of 297
positive control, cystamine, a neuroprotectant used in a number of disease models 298
whose therapeutic benefit has been attributed to its inhibition of the TGs and caspase 3 299
(Jeitner, Delikatny, Ahlqvist, Capper, & Cooper, 2005), except that the concentration of 300
cystamine used was 130 times less than that of the LPHs. The highest TG inhibition 301
achieved by the LPHs obtained with Alcalase was 51%, which was observed in LPH 302
15A. 303
3.3. Determination of kinetic parameters 304
Considering the observed inhibition of the four enzymes under investigation, two LPHs, 305
60I+15A and 15A, were selected, and kinetics studies were performed to determine 306
their Km and Vmax values using the Lineweaver–Burk equation. 307
3.3.1. Kinetic parameters of PLA2 inhibition 308
The kinetic analysis revealed that the Km values for PLA2 inhibition were 3.25 µM for 309
LPH 60I+15A and 1.36 µM for LPH 15A when the inverse of the reaction velocity 310
(µmol/min) and the substrate concentration (µM) (from the Lineweaver-Burk equation) 311
were considered (Table 1). Both of the LPHs seemed to competitively inhibit PLA2312
activity because the Vmax remained almost constant whereas the ratio Vmax/Km decreased 313
(in the case of 60+15A). In the case of LPH 15A, the ratio Vmax/Km did not decrease, but 314
the Km value of LPH 15A was larger than that of the control; therefore, its inhibition 315
also appears to be the competitive type. 316
3.3.2. Kinetic parameters of COX-2 inhibition 317
COX-2 exhibited a Km of 5.146 µM in the kinetic assay without an inhibitor. When 318
LPHs 60I+15A or 15A were added to the reaction medium, the Km value was 17.51 µM 319
or 15.71 µM, respectively (Table 1). Additionally, the Vmax/Km ratio was lower in both 320
cases, indicating that the inhibition of COX-2 by the LPHs was not competitive or 321
uncompetitive but a mixed (non-competitive) inhibition. 322
3.3.3. Kinetic parameters of thrombin inhibition 323
As shown in Table 1, the Km of thrombin inhibition were 23.22 µM for LPH 60I+15A 324
and 32.56 µM for LPH 15A when the inverse of the reaction velocity (µmol/min) and 325
the substrate concentration (µM-1) (from the Lineweaver-Burk equation) were 326
considered. Both LPHs seemed to competitively inhibit thrombin because the Vmax327
remained almost constant whereas the Vmax/Km ratio decreased.  328
3.3.4. Kinetic parameters of TG inhibition 329
The kinetic parameters of TG inhibition were estimated using Lineweaver-Burk plots; 330
the Km value estimated for dansyl-CAD in this study was 12.61 µM, which was similar 331
to the results obtained by Lorand, Lockridge, Campbell, Myhrman, & Bruner-Lorand 332
(1971), who reported Km=14 µM with α-casein as an acceptor. For the hydrolysates, Km333
13.44 µM was obtained in the case of the hydrolysate 60I+15A and 14.56 µM was 334
obtained for the 15A hydrolysate. Therefore, the inhibition appears to be the mixed type 335
because the Vmax and the Vmax/Km ratio decreased.  336
337
4. Conclusions 338
Hydrolysates of a lupine protein isolate obtained using commercial proteases inhibited 339
the activity of some of the enzymes involved in the inflammatory pathway. Chronic 340
inflammation is associated with the development of several chronic diseases. Therefore, 341
the results of this study indicate the potential use of lupine protein hydrolysates in the 342
production of functional foods. Additionally, the addition of lupine protein hydrolysates 343
as ingredients may improve the nutritional value of a product. However, further studies 344
should be performed to elucidate the anti-inflammatory effects of lupine hydrolysates in 345
vivo. 346
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FIGURE CAPTIONS 438
Figure 1. Time-course of hydrolysis of LPI by Izyme and Alcalase (A) and Alcalase 439
(B).440
Figure 2. Inhibition of PLA2 activity by LPHs obtained using Izyme followed by 441
Alcalase (A) and using Alcalase (B). Values marked with different letter are 442
significantly different (P<0.05).443
Figure 3. Inhibition of COX-2 activity by LPHs obtained using Izyme followed by 444
Alcalase (A) and using Alcalase (B). Values marked with different letter are 445
significantly different (P<0.05).446
Figure 4. Inhibition of thrombin activity by LPHs obtained using Izyme followed by 447
Alcalase (A) and using Alcalase (B). Values marked with different letter are 448
significantly different (P<0.05)449
Figure 5. Inhibition of transglutaminase activity by LPHs obtained using Izyme 450
followed by Alcalase (A) and using Alcalase (B). Values marked with different letter 451
are significantly different (P<0.05).452
TABLES 
Table 1. Values of Vmax and the ratios Vmax/Km for controls and inhibitors obtained from 
Lineweaver-Burk equation for different enzymes.  
ENZYME PLA2 COX-2 Thrombin TG-2 
Vmax Vmax/Km Vmax Vmax/Km Vmax Vmax/Km Vmax Vmax/Km
Control 1.01 0.83 15.64 3.04 17.88 1.09 7288 578.0
60I+15A 1.16 0.36 11.66 0.67 17.50 0.75 5072 377.4
15A 0.97 0.71 11.06 0.70 19.27 0.59 5871 403.2
Vmax is expressed in µmol/min 
Km is expressed in µM 
Table(s)
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